Author Archives: Bruno Quinney

#AbbVie #Cell and gene therapy #CRISPR Therapeutics #Eli Lilly #Hansa Biopharma #Resolution Therapeutics #Vertex

Cell and gene therapies – looking forward

Drug Discovery World speaks to key players in the cell and gene therapy sector to learn about the opportunities and challenges in this promising but difficult treatment area. … Read More

#Exclusive Content

#AI #Charles River #Emulate #Lab automation #Promega #SLAS2026

SLAS2026: Day Two Round-Up

DDW covers some of the biggest announcements from the second day of SLAS2026.     Emulate showcases organ-chip platform at SLAS2026   Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform. Read more…   Charles River and… Read More

#News

London cancer hub
#Cancer research #Institute of Cancer Research #Lab space #London Cancer Hub #The Royal Marsden NHS Foundation Trust

London Cancer Hub secures approval for £1bn expansion plans 

The London Cancer Hub has secured approval for a £1 billion ($1.4 billion) expansion, bringing state-of-the-art cancer research and lab space to the UK.   London Cancer Hub’s expanded district promises to be one of the world’s most ambitious life sciences clusters, with 12 acres dedicated to accelerating cancer research, treatment and commercial… Read More

#Cancer Research #News

Gene editing
#Bacteria #Gene editing #Purification technology #SLAS2026

Omega Bio-tek presents automation-friendly workflow 

Manufacturer Omega Bio-tek has presented a new workflow offering a high-throughput, automation-friendly platform at SLAS2026.  The workflow, developed in collaboration with Dynamic Devices, integrates the M1272 Mag-Bind Endo-free Plasmid Midi Kit. It is designed to meet the growing demand for scalable, endotoxin-free plasmid purification, which the company says is suitable for sensitive downstream applications including transfection, viral… Read More

#News

#AI #Lab automation #SLAS2026

UniteLabs presents AI-ready lab automation system

UniteLabs has presented its Operating System at SLAS2026, promising to unlock AI-ready lab automation.  The Operating System replaces vendor-specific instruments and software with an open, Python-based infrastructure, giving lab automation engineers and scientists full control and transparency over their workflows. Use cases at launch included liquid handling and closed loop… Read More

#News

Artificial intelligence
#AI #Life sciences #SLAS2026

Cenevo launches AI agents to accelerate lab operations 

Cenevo has advanced towards agentic labs with the launch of two new AI agents.  The company, which specialises in lab management systems, automation, orchestration, data management and AI technology for life sciences, hopes the new agents will help scientists operate faster, smarter and with less manual overhead.  The first new agent,… Read More

#News

amino acids chain
#Cellular assays #Promega #SLAS2026

Promega launches cellular target engagement platform 

Promega has launched a new live-cell target engagement platform aiming to close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins.  TheTarSeer BRETSA Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. … Read More

#News

#High throughput screening #Parse Biosciences #SLAS2026

QIAGEN presents new sample processing system at SLAS2026 

QIAGEN has presented its new high-throughput sample processing system at SLAS2026.  The QIAsprint Connect marks the company’s entry into high-throughput sample processing, enabling preparation of up to 192 samples per run while reducing plastic consumption.   QIAGEN hopes the system can address demand for automation and throughput in applications,… Read More

#News

#Assays #Charles River #SLAS2026

Charles River and Synthace to advance assay development 

Charles River Laboratories has announced a collaboration with software and assay developer Synthace to advance assay development in drug discovery.  As part of the collaboration announced at SLAS2026, Charles River will give its clients access to Synthace’s approach to developing, automating and transferring more robust assays, which it says are faster and… Read More

#Business & Investment #News

#Drug development #Emulate #FDA #SLAS2026

Emulate showcases organ-chip platform at SLAS2026 

Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform.  The AVA Emulation System, launched in June 2025, is a self-contained instrument that cultures, incubates, and images up to 96 independent organ-chip samples in… Read More

#News

#Assays #Drug discovery #Oncology #Revvity #SLAS2026 #SPT Labtech

SLAS2026: Day One Round-Up  

DDW covers some of the biggest announcements from the first day of SLAS2026.     Carterra launches high-throughput SPR instrument   High-throughput technology provider Carterra  launched its Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument – the industry’s first 48-channel SPR platform. The instrument has been designed to deliver 12-fold higher throughput versus the… Read More

#News

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK government #University of Sydney

DDW Highlights: 10 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative therapies showed the way to more effective cancer treatments. Elsewhere, how can… Read More

#Podcasts

Non-small cell lung cancer
#Biomica #Clinical trial #Kidney cancer #Lung cancer

Collaboration to advance drug enhancing immunotherapy response 

Biotech company Shanghai Lishan has entered a licensing agreement with computational chemistry company Evogene for a treatment enhancing immunotherapy response.  BMC128, a potential first-in-class, microbiome-based therapeutic, is designed to enhance anti-tumour activity. The treatment, developed by Evogene’s subsidiary Biomica, is a live biopharmaceutical consortium composed of four human gut… Read More

#Business & Investment #News

T cells attack a cancer cell
#Anti-inflammatory #Canada #GPCRs #Immuno-oncology

Kainova secures funding to develop GPCR-targeting therapies 

Biopharmaceutical company Kainova Therapeutics has secured $32 million CAD (US $24 million) to accelerate the development of immuno-oncology and inflammation therapies.  This financing round was led by Investissement Québec, with funds set to support Kainova’s advancement of GPCR-targeting therapies.  The company’s lead asset DT-7012, a Treg-depleting anti-CCR8 antibody,… Read More

#Business & Investment #News

#FDA #Priority Review #Rare diseases #SynaptixBio

US Senate reauthorises Priority Review Voucher scheme 

The US Senate has reauthorised the US Food and Drug Administration (FDA)’s Priority Review Voucher (PRV), helping biotech companies to develop rare disease drugs.  The PRV programme, which incentivises rare disease drug development, was reauthorised on 30 January, with President Donald Trump signing the bill. … Read More

#News #Regulatory

#Drug discovery #High throughput screening #Revvity #SLAS2026

Revvity launches high-impact discovery platform 

Revvity launched multiple new discovery platforms and technologies at SLAS2026, all designed to accelerate high-throughput drug discovery workflows.   The company debuted its Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation.   The Opera Phenix OptIQ high-content screening system is designed to reduce bottlenecks in phenotypic screening and… Read More

#News